Compare SLDB & BLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDB | BLDP |
|---|---|---|
| Founded | 2013 | 1979 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.0M | 657.3M |
| IPO Year | 2017 | 2009 |
| Metric | SLDB | BLDP |
|---|---|---|
| Price | $6.17 | $1.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 11 |
| Target Price | ★ $18.71 | $3.38 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,000.00 | N/A |
| Revenue This Year | N/A | $14.39 |
| Revenue Next Year | N/A | $38.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $1.43 |
| 52 Week High | $11.45 | $6.57 |
| Indicator | SLDB | BLDP |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 34.29 |
| Support Level | $5.38 | N/A |
| Resistance Level | $6.77 | $2.25 |
| Average True Range (ATR) | 0.46 | 0.08 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 63.64 | 36.25 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.